CareDx (NASDAQ: CDNA) reported Q2 EPS of $0.04, $0.08 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $41.8 million versus the consensus estimate of $35.61 million.

“Throughout this challenging time, our team at CareDx successfully executed across our initiatives and never wavered from our commitment to improving the lives of transplant patients. Our performance in the second quarter, highlighted by strong growth and robust results from RemoTraC, is a testament to our patient-focus and dedication,” said Peter Maag, CareDx Chairman and Chief Executive Officer. “As we look to the second half of this year, while uncertainty continues, what remains clear is the dedication of our team, our ability to navigate through this time and our confidence to be able to continue to deliver durable long-term operational growth.”

GUIDANCE:

While CareDx experienced improved trends in the second quarter, due to the continued uncertainties with respect to the COVID-19 pandemic, CareDx will not be providing guidance at this time.

For earnings history and earnings-related data on CareDx (CDNA) click here.